The influence of topical diclofenac sodium on the ocular hypotensive effect of latanoprost in glaucoma patients.

Rana Sorkhabi, Rakhshande Alipanahi, Amir Eftakhari-Milani, Leila Ghojazadeh

Journal: Journal of glaucoma 2011;20(4):240-3

PMID: 20577116

Abstract

PURPOSE

To evaluate the effect of diclofenac sodium 0.1% on reducing intraocular pressure (IOP) by latanoprost 0.005% in glaucoma patients.

PATIENTS AND METHODS

Twenty-two patients with bilateral primary open angle glaucoma were enrolled in this study. All patients had been given only latanoprost for at least 4 weeks. Topical diclofenac sodium was additionally applied to one eye (dicloptin group), whereas hydroxypropyl methyl cellulose was administered into the other eye (control group); both 4 times a day for 2 weeks. IOP measurement was performed before and 2 weeks after the administrations, and also 2 weeks after discontinuing additional ophthalmic solutions.

RESULTS

No significant difference was observed in the IOPs before additional administration of ophthalmic solution between the dicloptin group and the control group (P=0.47). Additional administration of diclofenac sodium increased mean IOP from 15.73±1.75 to 17.32±2.23 mm Hg (P=0.01). This increase was reversed 2 weeks after discontinuing additional solutions (P=0.80); however, no significant difference in mean IOP was observed in the control group after administration and after discontinuing the additional medication (P=0.94 and 0.84, respectively).

CONCLUSIONS

Topical diclofenac sodium may interfere with the IOP lowering effect of latanoprost in glaucoma patients; therefore this interference should be noted in coadministration of these drugs.

Address: Department of Ophthalmology, Nikookari Eye Center, Tabriz University of Medical Sciences, Tabriz, Iran.
Bant logo

© Copyright 2026, Nutrition Evidence

NED wishes to thank the following organisations for their support:

We use cookies to improve your experience and analyze site traffic with Google Analytics. By continuing to use our site, you agree to our use of cookies. Learn more.